SI-BONE Projects 2025 Revenue of Up to $200.9 Million

Reuters
Jan 12
SI-BONE Projects 2025 Revenue of Up to $200.9 Million

SI-BONE Inc. has announced its preliminary financial results for the fourth quarter and full year 2025. The company reported worldwide revenue between $56.2 million and $56.3 million for the fourth quarter, representing approximately 15% growth compared to the prior year period. U.S. revenue for the same period reached between $53.3 million and $53.4 million, with around 14% growth. The number of active physicians in the U.S. increased by about 250 to approximately 1,640, marking an 18% rise. For the full fiscal year 2025, SI-BONE expects worldwide revenue between $200.8 million and $200.9 million, an increase of about 20%. U.S. revenue is projected to be between $190.9 million and $191.0 million, reflecting a 21% growth rate. The company ended the year with cash and equivalents of roughly $147.7 million, generating approximately $2.0 million in net cash during the fourth quarter. These figures indicate significant year-over-year growth in both revenue and active physician engagement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SI-BONE Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10